FindTrial
Sign In

NT219

DRUG2 trials

Sponsors

TyrNovo Ltd., University of Colorado, Denver

Conditions

Colorectal AdenocarcinomaHead and Neck CancerHead and Neck Squamous Cell CarcinomaMetastatic Solid TumorRecurrent Solid TumorSolid Tumor, AdultSquamous Cell Carcinoma of Head and Neck

Phase 1

A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer
CompletedNCT04474470
TyrNovo Ltd.Colorectal Adenocarcinoma, Head and Neck Cancer, Metastatic Solid Tumor +3
Start: 2020-09-03End: 2024-05-08Updated: 2024-09-19
NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Active, not recruitingNCT06919666
University of Colorado, DenverHead and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Start: 2025-06-12End: 2031-02-01Target: 29Updated: 2026-07-02

Related Papers

Abstract 5181: Early activity and biomarker evaluation of NT219 in combination with cetuximab in a Phase 1/2 study of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Cancer Research2024-03-221 citations
27O Interim results of a phase I/II trial of NT219 in combination with cetuximab in patients with advanced/metastatic squamous cell carcinoma of the head and neck (SCCHN)
ESMO Open2024-02-011 citations
Interim safety and efficacy results from a phase 1 study of NT219 in adults with advanced solid tumors.
Journal of Clinical Oncology2022-06-01
A phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 injection alone and in combination with cetuximab in adults with advanced solid tumors and head and neck cancer.
Journal of Clinical Oncology2021-05-201 citations